Evidence map›Paper›PMID 36564544›Full record

ArticleScientific reports2022

Absence of early platelet increment in healthy mice during decitabine treatment.

Juliane Baumann, Markus Spindler, Yannick Throm, Michael Lübbert, Markus Bender

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Juliane Baumann *Institute of Experimental Biomedicine - Chair I, University Hospital Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.
Markus Spindler *Institute of Experimental Biomedicine - Chair I, University Hospital Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.
Yannick ThromInstitute of Experimental Biomedicine - Chair I, University Hospital Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.
Michael LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
Markus BenderInstitute of Experimental Biomedicine - Chair I, University Hospital Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany. Bender_M1@ukw.de.
Universitätsklinikum Würzburg · DEUniversity Medical Center Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on megakaryocytes and the bone marrow, however, is understudied. We show that an early platelet increment was not detectable in healthy mice during decitabine treatment. Analyses of bone marrow sections revealed vessels with dilated lumina, decreased cellularity, but increased number of red blood cells and the presence of (pro)platelet-like particles. Taken together, decitabine treatment of healthy mice does not induce an early platelet increment, but affects the bone marrow.

Indexed as

AzacitidineMyelodysplastic SyndromesAnimalsBlood PlateletsDecitabineMegakaryocytesMiceTreatment OutcomeAzacitidineDecitabine

Identifiers

PMID36564544
PMCPMC9789030
OpenAlexW4312181061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.